Spectral AI Inc

Spectral AI Inc(MDAI)股票分析

$1.495

+0.125 (+8.33%)收盤時

Loading chart…
最高
1.530
開盤
1.410
成交量加權均價
1.47
成交量
166.46K
市值
31.47M
最低
1.400
成交金額
245.53K
企業價值/稅息折舊攤銷前利潤(TTM)
-1.19

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

AI 分析 of Spectral AI Inc (MDAI)

買進

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

估值指標

Spectral AI Inc(MDAI)目前預期本益比為 52.36,5 年平均預期本益比為 6.80。

預期本益比

嚴重高估
5 年均值 P/E
6.80
目前P/E
52.36
高估
25.58
低估
-11.98

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
-18.84
目前EV/EBITDA
-1.19
高估
3.75
低估
-41.44

預期股價營收比

合理
5 年均值 P/S
4.76
目前P/S
1.37
高估
9.54
低估
-0.02

Alphio AI 對 MDAI 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%MDAI

$2.22

情境價格

基

基準

基準 · 50%MDAI

$2.20

情境價格

悲

悲觀

悲觀 · 25%MDAI

$1.52

情境價格

事件時間軸

2026-10-06 (ET)

09:00:00

Spectral AI Submits NTAP Application to CMS

2026-10-01 (ET)

09:00:00

Spectral AI Completes First Site Initiation Visit for Clinical Study

2026-07-08 (ET)

09:30:00

Spectral AI Appoints Darcy Bajko as Chief Commercial Officer

2026-05-26 (ET)

07:10:00

Spectral AI's DeepView System Receives FDA De Novo Classification

2026-04-08 (ET)

08:50:00

Spectral AI Appoints David McGuire as CFO

資訊

MDAI 常見問題 —— 由 Alphio AI 解答

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Spectral AI Inc is a good buy right now due to its recent FDA clearance for the DeepView System, which is expected to drive revenue growth, with an anticipated revenue of approximately $18.5 million for the year. The current price is $1.52, significantly below the analyst price target of $4, indicating a potential upside of 163.16%. However, the company has a high forward P/E of 52.36, indicating potential valuation concerns as it continues to navigate operational losses.

暫無貼文

註冊或登入後參與討論

相關文章

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易